Assess and document the ongoing impact of the Nagoya Protocol and possibly related national Access and Benefit Sharing (ABS) legislation, on sharing of influenza isolates and gene sequences in relation to influenza vaccine R&D; share findings with key policymakers (e.g., ministries of health/agriculture and global trade); and determine strategies to address potential unintended consequences.
US CDC has supported this work through WHO working groups and input to the WHO World Health Assembly.
WHO has published several reports on the public health implications of the Nagoya protocol, such as Implementation of Decision WHA72(12), which included requests related to influenza virus sharing:
Report on influenza virus sharing
Summary report on national legislation and regulatory measures related to influenza
WHO: Public health implications of the Nagoya Protocol
IFPMA noted agreement “across UN agencies and member states, along with science, public health, and legal experts, civil society, foundations, and industry… that access to pathogen samples and their genetic information is fundamental to improved preparedness and response.” One of the “approaches under consideration to improve pandemic preparedness and response related to pathogen sharing” includes “changes to the Convention on Biological Diversity’s Nagoya Protocol expressly to exclude outbreak pathogens…”.